Notice: This company has been marked as potentially delisted and may not be actively trading. NASDAQ:FOMX Menlo Therapeutics (FOMX) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Menlo Therapeutics Stock (NASDAQ:FOMX) 30 days 90 days 365 days Advanced Chart Remove Ads Get Menlo Therapeutics alerts:Sign Up Key Stats Today's Range$2.99▼$2.9950-Day Range$2.99▼$2.9952-Week Range$1.97▼$4.84VolumeN/AAverage Volume518,350 shsMarket Capitalization$184.12 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewFoamix Pharmaceuticals Ltd., a late clinical-stage specialty pharmaceutical company, develops and commercializes foam-based formulations for dermatological therapy in the United States, France, Denmark, and Germany. Its lead product candidates include FMX101, a novel topical foam formulation of the antibiotic minocycline that has completed third pivotal Phase III clinical trial for the treatment of moderate-to-severe acne; and FMX103, which is in Phase III clinical trial for the treatment of moderate-to-severe papulopustular rosacea. The company's product pipeline includes FCD105 and FMX109 for the treatment of moderate-to-severe acne vulgaris; and FMX110 for the treatment of papulopustular rosacea. Foamix Pharmaceuticals Ltd. has development and license agreements with Bayer HealthCare AG; LEO Pharma A/S; Mylan N.V.; and Actavis plc. The company was founded in 2003 and is headquartered in Rehovot, Israel.Read More… Remove Ads Receive FOMX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Menlo Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address FOMX Stock News HeadlinesPatient advocate startup Solace is set to be valued at over $300 million in new funding round from Menlo VenturesMarch 26, 2025 | businessinsider.comHow to Watch Local FOX Stations Without CableNovember 13, 2024 | msn.comCrypto Genius: 12,000% in 12 months? [Here’s how]We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.April 1, 2025 | Paradigm Press (Ad)Michael J. Fox Foundation taps Palo Alto AI firmOctober 29, 2024 | bizjournals.comMenlo Club Unboxing & Review ¦ Is It Worth It¿October 18, 2024 | msn.comSelonterra Awarded Second Grant from The Michael J. Fox Foundation for Parkinson's ResearchOctober 9, 2024 | msn.comMenlo Security Exceeds $100M ARR, Delivers Secure Enterprise Browser Market LeadershipOctober 1, 2024 | tmcnet.comBrowser security startup Menlo annual recurring revenue reaches $100 millionOctober 1, 2024 | reuters.comSee More Headlines FOMX Stock Analysis - Frequently Asked Questions How were Menlo Therapeutics' earnings last quarter? Menlo Therapeutics Inc. (NASDAQ:FOMX) released its earnings results on Monday, November, 11th. The specialty pharmaceutical company reported ($0.41) earnings per share for the quarter, missing the consensus estimate of ($0.34) by $0.07. What other stocks do shareholders of Menlo Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Menlo Therapeutics investors own include Sorrento Therapeutics (SRNE), Pfizer (PFE), Amarin (AMRN), Bristol-Myers Squibb (BMY), Sangamo Therapeutics (SGMO), Anavex Life Sciences (AVXL) and CRISPR Therapeutics (CRSP). Company Calendar Last Earnings11/11/2019Today3/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Medicinals & Botanicals Sub-IndustryN/A Current SymbolNASDAQ:FOMX CIK1606645 Webwww.foamix.com Phone972-8931-6233FaxN/AEmployees80Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($1.70) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-74,160,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-100.58% Return on Assets-81.39% Debt Debt-to-Equity Ratio0.24 Current Ratio5.72 Quick Ratio5.72 Sales & Book Value Annual Sales$3.60 million Price / Sales51.15 Cash FlowN/A Price / Cash FlowN/A Book Value$1.70 per share Price / Book1.76Miscellaneous Outstanding Shares61,580,000Free FloatN/AMarket Cap$184.12 million OptionableOptionable Beta1.66 20 High-Yield Dividend Stocks that Could Ruin Your RetirementAlmost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.Get This Free Report This page (NASDAQ:FOMX) was last updated on 4/1/2025 by MarketBeat.com Staff From Our PartnersNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredRetirement Nightmare? It’s Already Happening.The market is on edge. Every day, another company slashes its dividend, leaving investors scrambling. Intel...Investors Alley | SponsoredNew “Trump” currency proposed in DCA former U.S. Presidential Advisor has come forward with a stern warning to investors: “Get out of tech, no...Paradigm Press | Sponsored10X Bigger than AI, quantum, EVs, crypto, and robotics combined?World Economic Forum: "Arguably the Most Exciting Human Discovery Since Fire" Sam Altman, Bill Gates, and M...Stansberry Research | SponsoredLive Footage From Elon Musk’s “Area 51”What’s happening inside this nondescript building in South Memphis is so incredible… That Elon’s competitor...Brownstone Research | SponsoredTermination: 18F (read immediately)Have you ever heard of the government's 18F program? It helped manage digital services across the governmen...Altimetry | Sponsored“Massive Financial Reset Is Coming”The U.S. markets will see a massive reset, beginning days from now. But the "reset" isn't what you might ex...InvestorPlace | SponsoredGold Hits $3,000… Here’s How You Can Get More for Under $20With gold surging to record highs, currently trading above $3,000 an ounce, and central banks aggressively sto...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Menlo Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Menlo Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.